DuPont 2011 Annual Report Download - page 93

Download and view the complete annual report

Please find page 93 of the 2011 DuPont annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 120

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120

Table of Contents E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (continued)
(Dollars in millions, except per share)
Additional Segment Details
2011 included the following pre-tax benefits (charges):
2011
Agriculture1,2 $ (225)
Industrial Biosciences 3,4 (79)
Nutrition & Health 3,4 (126)
Performance Coatings 43
Performance Materials4,5 47
Other4(28)
$ (408)
1. Included a $(50) charge recorded in research and development expense in connection with a milestone payment associated with a Pioneer licensing agreement. Since this milestone was
reached before regulatory approval was secured by Pioneer, it was charged to research and development expense.
2. Included a $(175) charge recorded in cost of goods sold and other operating charges associated with the company's process to fairly resolve claims associated with the use of Imprelis®.
See Note 15 for additional information.
3. Included a $(182) charge for transaction related costs and the fair value step-up of inventories that were acquired as part of the Danisco transaction, which impacted the segments as
follows: Industrial Biosciences - $(70) and Nutrition & Health - $(112).
4. Included a $(50) restructuring charge primarily related to severance and related benefit costs associated with the Danisco acquisition impacting the segments as follows: Industrial
Biosciences - $(9); Nutrition & Health - $(14); Performance Coatings - $3; Performance Materials - $(2); and Other - $(28). See Note 4 for additional information.
5. Included a $49 benefit recorded in other income, net associated with the sale of a business.
2010 included the following pre-tax benefits (charges):
2010
Agriculture 1$ (50)
Electronics & Communications28
Performance Chemicals210
Performance Coatings 2(6)
Performance Materials 216
Safety & Protection25
Other21
$ (16)
1. Included a $(50) charge in research and development expense for an upfront payment related to a Pioneer licensing agreement. Since this payment was made before regulatory approval
was secured by Pioneer, it was charged to research and development expense.
2. Included a $34 net reduction (increase) in estimated restructuring costs related to restructuring programs impacting the segments as follows: Electronics & Communications – $8;
Performance Chemicals – $10; Performance Coatings – $(6); Performance Materials – $16; Safety & Protection – $5; and Other – $1.
F-44